The healthcare company Expansion Therapeutics is currently looking to raise funds for medical research. It is looking to get funding in an effort to find a cure to the medical condition known as myotonic dystrophy type 1. This is a condition that causes muscular dystrophy in adults when the RNA becomes toxic. In order to come up with the funds for the medical research, Expansion Therapeutics has looked to get aid from other companies so that it can come up with the needed capital. So far, the company has made considerable progress as it has currently raised over $55 million. The companies that have helped Expansion Therapeutics with the fund raising include Sanofi Ventures, Novartis Venture Fund, Kleiner Perkins and 5AM Ventures. With these companies contributing to the cause, it is likely that a cure for myotonic dystrophy will be developed in the near future.
When looking to fund the research, Expansion Therapeutics has looked to find a medical researcher. In a recent announcement, it was revealed that Dr. Mathew Disney Ph D will be leading the research efforts. Dr. Disney will spend time evaluating the condition and then look for ways to cure it. With his efforts, a cure for myotoic dystrophy type 1 can be realistically attainable.
One of the individuals who has led the effort in finding a cure for this condition is Scott Rocklage. He is the current managing partner of 5AM Ventures. In recent months, he has spent a lot of his time learning about myotonic dystrophy type 1 and looking to come up with funds for a cure. Rocklage has contributed to the fund raising and believes that the funds will lead to finding a cure for myotonic dystrophy. Scott has spent three decades in healthcare management. While working in healthcare management, Scott has been able to use his leadership and expertise to help numerous organizations in the medical field reach their various goals. During his career, he has helped get numerous medications approved by the Federal Food and Drug Administration. These include key medications such as Cubicin, Teslascan and Omniscan. He has also submitted a number of other medications for trial as well.
Connect with Dr. Scott Rocklage on LinkedIn.